# A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

> **NCT02900664** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 283 (actual)

## Conditions studied

- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

## Interventions

- **BIOLOGICAL:** PDR001
- **BIOLOGICAL:** ACZ885
- **BIOLOGICAL:** CJM112
- **DRUG:** TMT212
- **DRUG:** EGF816

## Key facts

- **NCT ID:** NCT02900664
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-23
- **Primary completion:** 2021-03-17
- **Final completion:** 2021-03-17
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900664, "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02900664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*